Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone for apathy in schizophrenia
NCT06482554Phase 3Recruiting
- Sponsor
- LSU Health Shreveport
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lumateperone in schizophrenia and schizoaffective disorder (2 arms), sponsored by LSU Health Shreveport. Primary endpoint: Apathy Evaluation Scale - Clinician at 8 weeks. Started Jun 2024; status: recruiting.
02
Drugs
lumateperone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT06482554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482554.